CRL4(CRBN) E3 ubiquitin ligase · PROTEIN COMPLEX · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-14CRL4(CRBN) E3 ubiquitin ligase shows approved-linked disease relevance led by multiple myeloma. 5 more disease programs remain visible in the same review block. 5 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt Q96SW2. Start with multiple myeloma, then reuse UniProt Q96SW2 as the stable protein anchor across project notes and exports.
Start with multiple myeloma, then reuse UniProt Q96SW2 as the stable protein anchor across project notes and exports.
CRL4(CRBN) E3 ubiquitin ligase shows approved-linked disease relevance led by multiple myeloma. 5 more disease programs remain visible in the same review block. 5 linked drugs remain visible in the same block.
Start review with multiple myeloma because it currently carries approved-linked support. Linked drugs include IBERDOMIDE, LENALIDOMIDE, LENALIDOMIDE HYDROCHLORIDE MONOHYDRATE, POMALIDOMIDE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyProtein cereblon
Review this target as CRL4(CRBN) E3 ubiquitin ligase, mapped to UniProt Q96SW2. ChEMBL maps the protein component as Protein cereblon. Sequence length is 442 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats CRL4(CRBN) E3 ubiquitin ligase as ChEMBL target CHEMBL3833061, mapped to UniProt Q96SW2. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether CRL4(CRBN) E3 ubiquitin ligase is the right protein anchor across sources, using UniProt Q96SW2 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why multiple myeloma is currently framed as approved-linked support. It currently carries 5 linked drugs in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | CRL4(CRBN) E3 ubiquitin ligase |
| Target Type | PROTEIN COMPLEX |
| Organism | Homo sapiens |
| UniProt | Q96SW2 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Protein cereblon |
| UniProt Accession | Q96SW2 |
| Component Type | Protein |
| Sequence Length | 442 aa |
Protein cereblon
Review this target as CRL4(CRBN) E3 ubiquitin ligase, mapped to UniProt Q96SW2. ChEMBL maps the protein component as Protein cereblon. Sequence length is 442 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
CRL4(CRBN) E3 ubiquitin ligase shows approved-linked disease relevance led by multiple myeloma. 5 more disease programs remain visible in the same review block.
Start review with multiple myeloma because it currently carries approved-linked support. Linked drugs include IBERDOMIDE, LENALIDOMIDE, LENALIDOMIDE HYDROCHLORIDE MONOHYDRATE, POMALIDOMIDE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.